insitro
Daphne Koller's machine-learning-first drug company — discovers disease mechanisms from causal biology rather than screening existing compounds.
1. Core Product / Service
insitro (the name merges in silico + in vitro) applies machine learning to human disease biology, focused on discovering disease mechanisms — causal biological drivers — rather than screening known compounds [1]. Its platform pairs high-throughput biological data generation with ML: the Virtual Human™ engine for causal biology discovery and ChemML™ for small-molecule design [1]. Therapeutic focus spans metabolic disease, neuroscience, and oncology.
Its partnerships are the business model: Gilead (NASH), Bristol Myers Squibb (ALS), and Eli Lilly (metabolic / ML models for ADMET), with insitro in several deals retaining the clinical-development role [1][2].
2. Target Users & Pain Points
- Pharma partners who license validated targets or co-develop programs.
- Its own pipeline — insitro is building toward in-house candidates, with a first clinical-trial entry targeted for 2026 [1].
Pain solved: target selection is the highest-leverage failure point in drug R&D; insitro's causal-biology approach aims to pick better targets before chemistry begins, versus optimizing later stages.
3. Competitive Landscape
| Player | Positioning | Vs. insitro |
|---|---|---|
| recursion-pharmaceuticals | Phenomics + ML at scale | Recursion is data-scale screening; insitro is causal-mechanism discovery |
| isomorphic-labs | AlphaFold lineage, Alphabet | Structure-prediction anchor vs. disease-biology anchor |
| insilico-medicine | Pharma.AI generative design | Insilico is generative-chemistry-first; insitro is mechanism-first |
4. Unique Observations
- Founder as brand: Daphne Koller (Stanford professor, co-founder of Coursera, ex-Calico chief computing officer) gives insitro the strongest academic-AI pedigree in the sector — the "ML pioneer builds a biotech" archetype [1].
- Mechanism-first vs. molecule-first: insitro is the cleanest test of the thesis that AI's biggest drug-discovery leverage is earlier — in target/mechanism selection — whereas most peers (absci, chai-discovery, insilico-medicine) apply AI later to molecule/antibody design.
- The "eight years to a first trial" timeline: insitro's ~2026 first clinical entry, eight years after founding, is a reminder of how long even the best-capitalized AI-biotechs take to reach the clinic — counterweight to sector hype [1].
5. Financials / Funding
- Rounds: $100M Series A (2018), $100M Series A+ (2019), $143M Series B (2020), $400M Series C (2021, led CPP Investments with a16z, BlackRock, Arch, GV, Third Rock) — total
$743M ($800M per company) [1]. - Partnerships (potential value): Gilead (>$1B, $15M upfront), BMS (ALS, $50M upfront, >$2B potential), Lilly — combined deal value >$5B, ~$150M collaboration revenue received [1][2].
- Valuation: estimated $2.6–3.2B (2025) [1].
6. People & Relationships
- Founder / CEO: Daphne Koller.
- Partners: Gilead Sciences, Bristol Myers Squibb, Eli Lilly.
- Peers: recursion-pharmaceuticals, isomorphic-labs, insilico-medicine.
Sources
- [1] insitro — Lilly partnership announcement (2026-08-24)
- [2] insitro — BMS collaboration expansion (2026-08-24)